Northern Trust Corp Purchases 238,161 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Northern Trust Corp increased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 14.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,873,588 shares of the company's stock after buying an additional 238,161 shares during the period. Northern Trust Corp owned 0.06% of Takeda Pharmaceutical worth $24,806,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Blair William & Co. IL raised its stake in Takeda Pharmaceutical by 8.1% during the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock worth $162,000 after buying an additional 913 shares during the last quarter. Sage Rhino Capital LLC raised its stake in Takeda Pharmaceutical by 14.9% during the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock worth $157,000 after buying an additional 1,538 shares during the last quarter. Aaron Wealth Advisors LLC raised its stake in Takeda Pharmaceutical by 7.2% during the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock worth $331,000 after buying an additional 1,670 shares during the last quarter. OLD Mission Capital LLC raised its stake in Takeda Pharmaceutical by 13.7% during the fourth quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock worth $185,000 after buying an additional 1,687 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in Takeda Pharmaceutical by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock worth $69,000 after buying an additional 1,770 shares during the last quarter. Institutional investors own 9.17% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.6%

Shares of NYSE TAK opened at $14.36 on Monday. The stock has a market capitalization of $45.69 billion, a P/E ratio of 35.90, a P/E/G ratio of 0.24 and a beta of 0.26. The company has a 50-day moving average price of $14.87 and a 200-day moving average price of $14.00. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.43. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.